Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).

Alexander Stein,Mascha Binder,Salah-Eddin Al-Batran,Axel Hinke,Lisa Waberer,E. Goekkurt,Tobias Meyer,Donjete Statovci,R. Depenbusch,Jorge Riera-Knorrenschild,Sylvie Lorenzen,Thomas Jens Ettrich,Steffen Doerfel,Carsten Bokemeyer,Susanna Hegewisch-Becker

Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC): Results of the safety run-in phase of the phase II AVETUX trial (AIO-KRK-0216).

2018

Alexander Stein
Mascha Binder
Salah-Eddin Al-Batran
Axel Hinke
Lisa Waberer
E. Goekkurt
Tobias Meyer
Donjete Statovci
R. Depenbusch
Jorge Riera-Knorrenschild
Sylvie Lorenzen
Thomas Jens Ettrich
Steffen Doerfel
Carsten Bokemeyer
Susanna Hegewisch-Becker

3561Background: Single agent PD-1/L1 inhibition is efficacious in mismatch repair deficient tumours - about 5% of MCRC patients (pts). For the remaining MCRC pts the role of immunotherapy still nee...

Keywords:

Avelumab
Cetuximab
Cancer research
FOLFOX
Colorectal cancer
Physical therapy
Medicine
Immunotherapy
Oncology
in patient
single agent
DNA mismatch repair
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations